Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Request a FREE Sample of our FcRn Binding Kit!
Request a FREE Sample of our Fc gamma RI / CD64 Binding Kit !
Happy Holiday! Limited Keychain here with your next orderHappy Holiday! Limited Keychain here with your next order
Request a FREE sample of our GMP products! Request a FREE sample of our GMP products!
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| KL1-M52H9 | Mouse | Mouse Plasma Kallikrein / KLKB1 Protein, His Tag |  |
|
|
| KL1-H52H9 | Human | Human Plasma Kallikrein / KLKB1 Protein, His Tag (active enzyme, MALS verified) |  |
|
The purity of Human Plasma Kallikrein/KLKB1, His Tag (Cat. No. KL1-H52H9) is more than 90% and the molecular weight of this protein is around 75-90 kDa verified by SEC-MALS.
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Lanadelumab | 2372V1TKXK (UNII code); X124-G01; SHP-643; DX-2930; TAK-743 | Approved | Dyax Pharma | Takhzyro, 达泽优 | United States | Angioedemas, Hereditary | Dyax Corp | 2018-08-23 | Drug-Related Side Effects and Adverse Reactions; Hypotension; Coronavirus Disease 2019 (COVID-19); Hereditary Autoinflammatory Diseases; Angioedema; Angioedemas, Hereditary; Lung Injury | Details |
| Berotralstat | BCX-7353 | Approved | Biocryst Pharmaceuticals Inc | ORLADEYO | United States | Angioedemas, Hereditary | Biocryst Pharmaceuticals Inc | 2020-12-03 | Angioedemas, Hereditary | Details |
| Ecallantide | DX-88; EPI-KAL2; FOV-2302; CB-500929 | Approved | Dyax Pharma | Kalbitor | United States | Angioedema | Dyax Corp | 2009-12-01 | Macular Edema; Hereditary Angioedema Types I and II; Blood Loss, Surgical; Angioedemas, Hereditary; Retinal Vein Occlusion; Angioedema | Details |
| Lanadelumab | 2372V1TKXK (UNII code); X124-G01; SHP-643; DX-2930; TAK-743 | Approved | Dyax Pharma | Takhzyro, 达泽优 | United States | Angioedemas, Hereditary | Dyax Corp | 2018-08-23 | Drug-Related Side Effects and Adverse Reactions; Hypotension; Coronavirus Disease 2019 (COVID-19); Hereditary Autoinflammatory Diseases; Angioedema; Angioedemas, Hereditary; Lung Injury | Details |
| Berotralstat | BCX-7353 | Approved | Biocryst Pharmaceuticals Inc | ORLADEYO | United States | Angioedemas, Hereditary | Biocryst Pharmaceuticals Inc | 2020-12-03 | Angioedemas, Hereditary | Details |
| Ecallantide | DX-88; EPI-KAL2; FOV-2302; CB-500929 | Approved | Dyax Pharma | Kalbitor | United States | Angioedema | Dyax Corp | 2009-12-01 | Macular Edema; Hereditary Angioedema Types I and II; Blood Loss, Surgical; Angioedemas, Hereditary; Retinal Vein Occlusion; Angioedema | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Sebetralstat | KVD-900 | Phase 3 Clinical | Kalvista Pharmaceuticals | Angioedemas, Hereditary | Details |
| THR-149 | TG-758; THR-149 | Phase 2 Clinical | Bicycle Therapeutics, Thrombogenics Inc | Diabetic macular oedema; Diabetic Retinopathy; Diabetes Mellitus | Details |
| QLS-215 | QLS-215; STAR-0215 | Phase 2 Clinical | Quellis Biosciences Inc | Angioedemas, Hereditary | Details |
| NTLA-2002 | NTLA-2002 | Phase 2 Clinical | Intellia Therapeutics Inc | Angioedemas, Hereditary | Details |
| KVD-001 | KVD-001 | Phase 2 Clinical | Vantia Ltd | Diabetic macular oedema | Details |
| MDPK-67b | DM-107; MDPK-67b; MDPK-67 | Phase 1 Clinical | Med Discovery | Prostatic Neoplasms | Details |
| Feniralstat | KVD-824 | Phase 1 Clinical | Vantia Ltd | Hereditary Angioedema Types I and II; Angioedemas, Hereditary | Details |
| MSB-03 | MSB-03 | Phase 1 Clinical | Rosacea | Details | |
| ATN-249 | ATN-249 | Phase 1 Clinical | Attune Pharmaceuticals | Angioedemas, Hereditary | Details |
| Sebetralstat | KVD-900 | Phase 3 Clinical | Kalvista Pharmaceuticals | Angioedemas, Hereditary | Details |
| THR-149 | TG-758; THR-149 | Phase 2 Clinical | Bicycle Therapeutics, Thrombogenics Inc | Diabetic macular oedema; Diabetic Retinopathy; Diabetes Mellitus | Details |
| QLS-215 | QLS-215; STAR-0215 | Phase 2 Clinical | Quellis Biosciences Inc | Angioedemas, Hereditary | Details |
| NTLA-2002 | NTLA-2002 | Phase 2 Clinical | Intellia Therapeutics Inc | Angioedemas, Hereditary | Details |
| KVD-001 | KVD-001 | Phase 2 Clinical | Vantia Ltd | Diabetic macular oedema | Details |
| MDPK-67b | DM-107; MDPK-67b; MDPK-67 | Phase 1 Clinical | Med Discovery | Prostatic Neoplasms | Details |
| Feniralstat | KVD-824 | Phase 1 Clinical | Vantia Ltd | Hereditary Angioedema Types I and II; Angioedemas, Hereditary | Details |
| MSB-03 | MSB-03 | Phase 1 Clinical | Rosacea | Details | |
| ATN-249 | ATN-249 | Phase 1 Clinical | Attune Pharmaceuticals | Angioedemas, Hereditary | Details |
This web search service is supported by Google Inc.
A-Z
